Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

Venetoclax-azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall survival (OS) analysis of the VIALE-A study (NCT02993523). Here, long-term follow-up is presented to address survival bene...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	American journal of hematology 2024-04, Vol.99 (4), p.615-624
Hauptverfasser:	Pratz, Keith W, Jonas, Brian A, Pullarkat, Vinod, Thirman, Michael J, Garcia, Jacqueline S, Döhner, Hartmut, Récher, Christian, Fiedler, Walter, Yamamoto, Kazuhito, Wang, Jianxiang, Yoon, Sung-Soo, Wolach, Ofir, Yeh, Su-Peng, Leber, Brian, Esteve, Jordi, Mayer, Jiri, Porkka, Kimmo, Illés, Árpád, Lemoli, Roberto M, Turgut, Mehmet, Ku, Grace, Miller, Catherine, Zhou, Ying, Zhang, Meng, Chyla, Brenda, Potluri, Jalaja, DiNardo, Courtney D
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Chemotherapy Comorbidity Leukemia Neutropenia Placebos Remission Survival Thrombocytopenia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!